Graefen, Markus
Markus Graefen
VIAF ID: 278784970 ( Personal )
Permalink: http://viaf.org/viaf/278784970
Preferred Forms
- 100 1 _ ‡a Graefen, Markus
- 100 0 _ ‡a Markus Graefen
4xx's: Alternate Name Forms (1)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Correlation of MRI-lesion targeted biopsy vs. systematic biopsy gleason score with final pathologicalg gleason score after radical prostatectomy | |
Correlation of urine loss after catheter removal and early continence in men undergoing radical prostatectomy | |
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups | |
effect of lymph node dissection on cancer‐specific survival in salvage radical prostatectomy patients | |
effect of primary urological cancers on survival in men with secondary prostate cancer | |
erhöhte Proteinexpression des Transkriptionsfaktors TFAP2D ist mit einem aggressiven Tumorphänotyp des Prostatakarzinoms ohne ERG-Fusion assoziiert | |
External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients | |
Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy | |
Identifizierung prognostischer und klinischer Faktoren für das klnische Management des biochemischen Rezidivs nach radikaler Prostatektomie | |
Immunohistochemistry for prostate biopsy - impact on histological prostate cancer diagnoses and clinical decision making | |
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients | |
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant | |
Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores | |
klinische Auswirkung eines nicht-beurteilbaren chirurgischen Absetzungsrandes (Rx) nach radikaler Prostatektomie | |
Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data | |
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer | |
Martini-Prinzip Spitzenmedizin durch Spezialisierung, Ergebnistransparenz und Patientenorientierung | |
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients | |
Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis | |
Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients | |
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis | |
Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort | |
Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer |